Mable Pereira

Mable Pereira

Auto-generated profile, based on publicly available information

Mable Pereira

School of Medicine Lincoln American University Georgetown Guyana

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
MPMable Pereira
Mable Pereira
SMShenelle Menezes
Shenelle Menezes
AFAncy Jenil Franco
Ancy Jenil Franco
PMPatricia Marcolin
Patricia Marcolin
MTMark Tomera
Mark Tomera

29 January 2026 in Cancer Medicine
Verified
Journal Article
Open access
DADana Abou
Dana Abou
HTHusna Irfan Thalib
Husna Irfan Thalib
FAFayza Akil
Fayza Akil
SSSamia Zuhair Sabbagh
Samia Zuhair Sabbagh
HAHala Sofian Abou
Hala Sofian Abou
FHfatma hassan
fatma hassan
Introduction: Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (rel/ref) disease. This subgroup has historically faced poor prognoses with limited treatment options, prompting the development of novel immunotherapeutic strategies. Chimeric antigen receptor T‐cell (CAR T) therapy and bispecific antibodies (BsAbs) have emerged as transformative approaches in this setting. Methods: This narrative review compares these therapies across multiple domains, including mechanisms of action, clinical efficacy, safety profiles, logistics, cost, and accessibility. Results: CAR T therapies have demonstrated durable complete response rates (40%–60%) and extended progression‐free survival (median 11–12.5 months), but they are limited by complex manufacturing, high cost, and potentially severe toxicities. In contrast, BsAbs offer immediate, off‐the‐shelf availability, with promising efficacy and a more favorable safety profile that enables outpatient administration, although long‐term durability remains under investigation. Conclusion: This review provides clinicians with a comprehensive comparison to support evidence‐based treatment selection in rel/ref DLBCL.

30 October 2025 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
HAHussain Ali Almohammed
Hussain Ali Almohammed
HTHusna Irfan Thalib
Husna Irfan Thalib
KKKawthar Faisal Kushara
Kawthar Faisal Kushara
BSBushra Wadi Bin Saddiq
Bushra Wadi Bin Saddiq
BZBayan Mohammed Khair Al Zoabi
Bayan Mohammed Khair Al Zoabi
SAShaima Abuhulayqah
Shaima Abuhulayqah
Background: Vestibular migraine (VM) is a neurological disorder characterized by episodic vertigo in patients with migraine, contributing to substantial functional impairment. Although VM is relatively common, a consensus on effective prophylactic treatments is lacking. This systematic review aimed to evaluate the efficacy and safety of pharmacological and adjunct non‐pharmacological interventions for VM management. Methods: The systematic review was conducted following the PRISMA 2020 guidelines. PubMed, Web of Science, and Google Scholar were searched from inception to April 2025. Randomized controlled trials or cohort (retrospective and prospective) studies assessing prophylactic pharmacological or adjunct non‐pharmacological management in adults diagnosed with VM were included. The risk of bias was evaluated using the Cochrane RoB 2 and MINORS tools. Results: Nine studies (three RCTs, six cohort studies; total n = 687) met the inclusion criteria. Beta‐blockers, particularly propranolol, and antiepileptics, such as topiramate, consistently reduced VM symptoms, as measured using validated scales (Dizziness Handicap Inventory, Vertigo Symptom Scale, and Vestibular Activities of Daily Living). Anti‐CGRP monoclonal antibodies (erenumab and galcanezumab) showed favorable efficacy and tolerability. By contrast, calcium channel blockers and antidepressants yielded inconsistent outcomes. Vestibular rehabilitation, when used as an adjunct therapy, demonstrated functional benefits. Reported adverse effects were generally mild and treatment specific. Substantial heterogeneity in treatment protocols, outcome assessments, and follow‐up intervals precluded meta‐analysis; therefore, findings were synthesized qualitatively. Conclusion: Moderate‐quality evidence supports the use of propranolol and topiramate as first‐line prophylactic treatments for VM. Emerging data suggest that anti‐CGRP agents may be beneficial for refractory cases. Larger, rigorously designed trials are necessary to establish standardized and individualized treatment protocols.

5 February 2026 in Brain and Behavior
Verified
Journal Article
Open access
HTHusna Irfan Thalib
Husna Irfan Thalib
NFNuha Fatima
Nuha Fatima
FFFaaleha Heba Fakruddin
Faaleha Heba Fakruddin
HAHosna Hamidullah Ali
Hosna Hamidullah Ali
SKSariya Khan
Sariya Khan
FHfatma hassan
fatma hassan
Purpose: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by progressive disability. Emerging evidence has implicated gut microbiome dysbiosis, characterized by decreased short‐chain fatty acids (SCFAs)‐producing taxa and increased pro‐inflammatory species, in disturbed immune signaling, T‐helper17/T‐regulatory cells imbalance, disturbed tryptophan metabolism, and disrupted integrity of the blood–brain barrier. In this review, we summarize the mechanistic and therapeutic insights from studies that have explored the gut microbiome in MS. Method: We performed a literature search in PubMed, Scopus, Web of Science, and ClinicalTrials.gov from database inception to January 2025; only English‐language articles were included, comprising human MS cohorts and preclinical experimental autoimmune encephalomyelitis models. Of these, approximately 95 human and preclinical studies fulfilled the inclusion criteria. Evidence synthesis was narrative, without meta‐analysis. Finding: There has been a consistent depletion of beneficial genera such as Faecalibacterium and Roseburia, expansion of Akkermansia muciniphila, and reduction in microbial metabolites such as butyrate, propionate, and neuroactive indole derivatives in MS patients across studies. These changes promote intestinal permeability, exaggerated pro‐inflammatory cytokine responses, and microglial activation. The therapeutic approach of restoring microbial balance includes therapies such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and dietary interventions. Early trials have shown modest improvements in relapse rates, fatigue, immune profiles, and microbiome composition. Results across randomized studies are heterogeneous, with no significant clinical benefit in several. Pilot trials report modest reductions in relapse rate (RR ≈ 0.85) and fatigue (Cohen's d ≈ 0.3), but several double‑blind RCTs showed no significant benefit ( p > 0.05) in up to 40% of participants, highlighting variable effect sizes. Conclusion: Interventions aimed at the microbiome are promising as adjunct approaches to the treatment of MS, acting principally through the restoration of SCFAs, immune modulation, and strengthening of the gut‐brain axis. Larger, longer‐term randomized trials are required to confirm clinical efficacy, define responder phenotypes, and inform personalized microbiome‐based therapies.

15 February 2025 in Inflammopharmacology
Verified
Journal Article
Closed access
MPMable Pereira
Mable Pereira
AFAncy Jenil Franco
Ancy Jenil Franco
KCKarthik Chintharala
Karthik Chintharala
AVAna Carolina Putini Vieira
Ana Carolina Putini Vieira
AJAna Carolina Ventura de Santana de Jesus
Ana Carolina Ventura de Santana de Jesus
KRKristian Reich
Kristian Reich

29 May 2026 in Formosan Journal of Surgery
Verified
Journal Article
Open access
MPMable Pereira
Mable Pereira
Agata GrochowskaAgata Grochowska
Agata Grochowska
SKSariya Khan
Sariya Khan
RPRafael Dib Possiedi
Rafael Dib Possiedi
Background: Obesity is a well-established risk factor for hernia development, recurrence, and adverse perioperative outcomes, posing major challenges in patients undergoing abdominal wall reconstruction (AWR) or complex hernia repair (CHR). Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially approved for type 2 diabetes, have demonstrated substantial weight-loss benefits and are increasingly used for preoperative optimization. Methods: A systematic search of PubMed, Embase, and the Cochrane Library was conducted for studies published up to June 11, 2025, evaluating GLP-1RA use in obese adults undergoing AWR or CHR. Studies were selected using predefined criteria. Data were charted and synthesized thematically to assess preoperative weight loss, time to surgery, perioperative safety, wound complications, and feasibility. Results: Three observational studies including 65 obese patients undergoing AWR or CHR were identified. GLP-1RA use was associated with a shorter time to surgery (6.3–9.1 months) compared with controls (13.5–14.7 months) and moderate preoperative weight loss (11.3–14.9%). Thirty-day morbidity was lower or comparable in GLP-1RA groups. Reported adverse events were infrequent, non-serious, and manageable. Conclusion: Preoperative GLP-1RA therapy appears promising as a prehabilitation strategy; however, current evidence is limited to small, heterogeneous observational studies with significant risk of bias. These findings should be considered hypothesis-generating rather than practice-changing.